CDK12 and prostate carcinoma: In addition, a multicentre study also showed that prostate cancer patients with CDK12 mutations had lower PSA50 responses to androgen receptor pathway inhibitors (abiraterone or enzalutamide) and chemotherapy drugs than patients with other DDR gene defects (Figure 1I), suggestive of a worse prognosis of CDK12‐mutated prostate cancer patients.